Cargando…

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm

PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET tracer [(18)F]THK5317 (also known as (S)-[(18)F]THK5117) retention in different stages of Alzheimer’s disease; and study any associations with markers of hypometabolism and amyloid-beta deposition. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiotis, Konstantinos, Saint-Aubert, Laure, Savitcheva, Irina, Jelic, Vesna, Andersen, Pia, Jonasson, My, Eriksson, Jonas, Lubberink, Mark, Almkvist, Ove, Wall, Anders, Antoni, Gunnar, Nordberg, Agneta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932128/
https://www.ncbi.nlm.nih.gov/pubmed/26996778
http://dx.doi.org/10.1007/s00259-016-3363-z
_version_ 1782441013966536704
author Chiotis, Konstantinos
Saint-Aubert, Laure
Savitcheva, Irina
Jelic, Vesna
Andersen, Pia
Jonasson, My
Eriksson, Jonas
Lubberink, Mark
Almkvist, Ove
Wall, Anders
Antoni, Gunnar
Nordberg, Agneta
author_facet Chiotis, Konstantinos
Saint-Aubert, Laure
Savitcheva, Irina
Jelic, Vesna
Andersen, Pia
Jonasson, My
Eriksson, Jonas
Lubberink, Mark
Almkvist, Ove
Wall, Anders
Antoni, Gunnar
Nordberg, Agneta
author_sort Chiotis, Konstantinos
collection PubMed
description PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET tracer [(18)F]THK5317 (also known as (S)-[(18)F]THK5117) retention in different stages of Alzheimer’s disease; and study any associations with markers of hypometabolism and amyloid-beta deposition. METHODS: Thirty-three individuals were enrolled, including nine patients with Alzheimer’s disease dementia, thirteen with mild cognitive impairment (MCI), two with non-Alzheimer’s disease dementia, and nine healthy controls (five young and four elderly). In a multi-tracer PET design [(18)F]THK5317, [(11)C] Pittsburgh compound B ([(11)C]PIB), and [(18)F]FDG were used to assess tau pathology, amyloid-beta deposition and cerebral glucose metabolism, respectively. The MCI patients were further divided into MCI [(11)C]PIB-positive (n = 11) and MCI [(11)C]PIB-negative (n = 2) groups. RESULTS: Test-retest variability for [(18)F]THK5317-PET was very low (1.17–3.81 %), as shown by retesting five patients. The patients with prodromal (MCI [(11)C]PIB-positive) and dementia-stage Alzheimer’s disease had significantly higher [(18)F]THK5317 retention than healthy controls (p = 0.002 and p = 0.001, respectively) in areas exceeding limbic regions, and their discrimination from this control group (using the area under the curve) was >98 %. Focal negative correlations between [(18)F]THK5317 retention and [(18)F]FDG uptake were observed mainly in the frontal cortex, and focal positive correlations were found between [(18)F]THK5317 and [(11)C]PIB retentions isocortically. One patient with corticobasal degeneration syndrome and one with progressive supranuclear palsy showed no [(11)C]PIB but high [(18)F]THK5317 retentions with a different regional distribution from that in Alzheimer’s disease patients. CONCLUSIONS: The tau-specific PET tracer [(18)F]THK5317 images in vivo the expected regional distribution of tau pathology. This distribution contrasts with the different patterns of hypometabolism and amyloid-beta deposition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-016-3363-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4932128
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-49321282016-07-18 Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm Chiotis, Konstantinos Saint-Aubert, Laure Savitcheva, Irina Jelic, Vesna Andersen, Pia Jonasson, My Eriksson, Jonas Lubberink, Mark Almkvist, Ove Wall, Anders Antoni, Gunnar Nordberg, Agneta Eur J Nucl Med Mol Imaging Original Article PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET tracer [(18)F]THK5317 (also known as (S)-[(18)F]THK5117) retention in different stages of Alzheimer’s disease; and study any associations with markers of hypometabolism and amyloid-beta deposition. METHODS: Thirty-three individuals were enrolled, including nine patients with Alzheimer’s disease dementia, thirteen with mild cognitive impairment (MCI), two with non-Alzheimer’s disease dementia, and nine healthy controls (five young and four elderly). In a multi-tracer PET design [(18)F]THK5317, [(11)C] Pittsburgh compound B ([(11)C]PIB), and [(18)F]FDG were used to assess tau pathology, amyloid-beta deposition and cerebral glucose metabolism, respectively. The MCI patients were further divided into MCI [(11)C]PIB-positive (n = 11) and MCI [(11)C]PIB-negative (n = 2) groups. RESULTS: Test-retest variability for [(18)F]THK5317-PET was very low (1.17–3.81 %), as shown by retesting five patients. The patients with prodromal (MCI [(11)C]PIB-positive) and dementia-stage Alzheimer’s disease had significantly higher [(18)F]THK5317 retention than healthy controls (p = 0.002 and p = 0.001, respectively) in areas exceeding limbic regions, and their discrimination from this control group (using the area under the curve) was >98 %. Focal negative correlations between [(18)F]THK5317 retention and [(18)F]FDG uptake were observed mainly in the frontal cortex, and focal positive correlations were found between [(18)F]THK5317 and [(11)C]PIB retentions isocortically. One patient with corticobasal degeneration syndrome and one with progressive supranuclear palsy showed no [(11)C]PIB but high [(18)F]THK5317 retentions with a different regional distribution from that in Alzheimer’s disease patients. CONCLUSIONS: The tau-specific PET tracer [(18)F]THK5317 images in vivo the expected regional distribution of tau pathology. This distribution contrasts with the different patterns of hypometabolism and amyloid-beta deposition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-016-3363-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-03-21 2016 /pmc/articles/PMC4932128/ /pubmed/26996778 http://dx.doi.org/10.1007/s00259-016-3363-z Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Chiotis, Konstantinos
Saint-Aubert, Laure
Savitcheva, Irina
Jelic, Vesna
Andersen, Pia
Jonasson, My
Eriksson, Jonas
Lubberink, Mark
Almkvist, Ove
Wall, Anders
Antoni, Gunnar
Nordberg, Agneta
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
title Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
title_full Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
title_fullStr Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
title_full_unstemmed Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
title_short Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
title_sort imaging in-vivo tau pathology in alzheimer’s disease with thk5317 pet in a multimodal paradigm
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932128/
https://www.ncbi.nlm.nih.gov/pubmed/26996778
http://dx.doi.org/10.1007/s00259-016-3363-z
work_keys_str_mv AT chiotiskonstantinos imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT saintaubertlaure imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT savitchevairina imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT jelicvesna imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT andersenpia imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT jonassonmy imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT erikssonjonas imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT lubberinkmark imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT almkvistove imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT wallanders imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT antonigunnar imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm
AT nordbergagneta imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm